GeoVax raises ~$1M gross in registered direct offering priced at $2.31/share

GeoVax Labs, Inc.

Offering of 432,902 shares (or pre-funded warrants) at $2.31/share; net proceeds ~$865,000.
Concurrent private placement of Series A-1 and A-2 warrants for up to 432,902 shares each, exercisable at $2.31 after shareholder approval.
Existing warrants for 236,000 shares amended: exercise price reduced from $4.35 to $2.31, subject to shareholder approval.
Proceeds to fund R&D, manufacturing, clinical studies, and working capital.
H.C. Wainwright acted as sole placement agent; closing occurred February 17, 2026.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

GeoVax Labs, Inc. entered into Purchase Agreement with the purchasers party thereto valued at approximately $865,000 (effective 2026-02-13).

Action: entry
Agreement: equity purchase
Counterparty: the purchasers party thereto
Value: approximately $865,000
Effective: 2026-02-13

Exact text from the filing

On February 13, 2026, GeoVax Labs, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers party thereto, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), an aggregate of (i) 402,000 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 30,902 shares of Common Stock (the “Pre-Funded Warrant Shares”).

View on SEC.gov

303 material agreements filed in the last 30 days. Browse all material agreements →

GeoVax Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-004392

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.